Skip to main content

Personalized CAR T Cell Therapy™

Learn More Today

You are here

Our Team

Ronald P. Dudek

Founder and President

Mr. Dudek is the founder of CAR T Cells, LLC, a consulting company serving investment, biopharmaceutical, and consulting company clients.

He is the former Vice President of Commercial Strategy at Juno Therapeutics, Inc., and one of the first members of the company.

Mr. Dudek is the founder and former President of Restoration Oncology, Inc. (ROI), a CAR T cell company that developed CD19 CAR T cells for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Mr. Dudek's background includes 25 years of biotechnology business experience and 8 years of immunology research experience.


Eduardo Davila, PhD

Founder and Chief Science Officer

Dr. Davila is an associate professor of microbiology and immunology at the University of Maryland School of Medicine, as well as the program leader for the Tumor Immunology and Immunology Research Program at the Greenebaum Comprehensive Cancer Center at the University of Maryland. His research interests focus on developing novel T cell-based cancer therapies.

Dr. Davila is the inventor of Living Pharma's AT-CAR™ technology, and the inventor of the Universal Anti-Tag Chimeric Antigen Receptor Expressing T Cells and Methods of Treating Cancer patent.


Dr. Eduardo Davila wins life award for advances on successful platform to fight cancer using the body's own immune system. Read article.


Isai Peimer, PhD

From 2010 to 2016, Isai was a Managing Director at Medimmune Ventures, Astrazeneca's investment fund. Previously, Isai worked as a venture capitalist at Visium Asset Management. He was an investment banker at J.P. Morgan and a Specialty Pharmaceuticals analyst at Alliance Bernstein. Prior to Wall Street, Isai was a management consultant in the pharmaceutical and biotech industry; he began his career as a scientist at Merck.

Isai has served as board member of Adheron Therapeutics (Acquired by Roche), Ambit Biosciences (NASDAQ: AMBI, acquired by Daiichi Sankyo), Armaron Bio Ltd., Corridor Pharmaceuticals (acquired by Astrazeneca), Inotek Pharmaceuticals (NASDAQ: ITEK), Xencor (NASDAQ: XNCR) and The Ivy Foundation Biomedical Innovation Review Board at University of Virginia.

Isai is a graduate of Emory University where he earned a B.A. in Chemistry summa cum laude, and earned his M.B.A. from the Tuck School of Business at Dartmouth.


Aaron P. Rapoport, M.D.

Dr. Rapoport is a professor in the Department of Medicine, the Gary Jobson Professor of Medical Oncology and the Director of the Blood and Marrow Stem Cell Transplant Program in the Greenebaum Cancer Center, at the University of Maryland School of Medicine and Medical Center.

Dr. Rapoport is a board-certified hematologist and stem cell transplant (SCT) physician with more than 25 years of experience in the care of patients with hematopoietic neoplasms and benign hematologic disorders. He also conducts translational research that focuses on the use of co-stimulated and genetically modified autologous T cells and vaccines to enhance immune recovery after autologous stem cell transplants for hematologic malignancies.

In 2012, Dr. Rapoport was named the inaugural Gary Jobson Professor of Medical Oncology at the University of Maryland School of Medicine. He was also named a “Top Doc” by Baltimore Magazine in 2011, 2012, 2013, 2014, 2015 and 2016.